California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...